1295.TWO Synbio Tech Inc.
- Market cap
- TWD 1.68B
- P/E
- 10.9x
- P/B
- 1.27x
- ROE
- 10.4%
- Dividend yield
- 6.51%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 1295.TWO undervalued?
Graham number1295.TWO trades 21.4% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Synbio Tech Inc. fundamental analysis
No fundamental analysis for Synbio Tech Inc. yet.
Synbio Tech Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Synbio Tech Inc.
Synbio Tech Inc. manufactures and sells human healthcare products and probiotics for animals. It offers lactobacillus plantarum powder and derivatives of fermented lactic acid bacteria, as well as probiotics for dietary supplements, pets, economic animals, and plant preservation. The company also provides single probiotic strain and multi strain probiotics, and functional strain. Its functional strain includes SynForU-MemoryUp, a solution for brain health; Lactobacillus plan…
Full company profileSynbio Tech Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Synbio Tech Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 737M | 856M | 739M | 823M | 989M | 1.04B | 1.02B |
| Gross Profit | 390M | 446M | 361M | 419M | 541M | 555M | 508M |
| Operating Income | 159M | 187M | 102M | 143M | 209M | 198M | 153M |
| EBITDA | 237M | 268M | 201M | 231M | 316M | 294M | 330M |
| Net Income | 132M | 160M | 92.5M | 113M | 170M | 176M | 136M |
| EPS | 4.20 | 5.13 | 2.94 | 3.60 | 5.40 | 5.09 | 3.94 |
| Balance Sheet | |||||||
| Total Assets | 1.39B | 1.53B | 1.68B | 1.89B | 2.34B | 3.09B | 3.23B |
| Total Liabilities | 627M | 670M | 779M | 943M | 1.27B | 1.76B | 1.92B |
| Shareholders' Equity | 758M | 863M | 898M | 943M | 1.08B | 1.33B | 1.31B |
| Cash & Short-term Investments | 217M | 393M | 416M | 347M | 469M | 270M | 305M |
| Total Debt | 450M | 506M | 629M | 732M | 954M | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | 212M | 263M | 187M | 214M | 262M | 143M | 186M |
| Capital Expenditure | 11.1M | 44.6M | 220M | 328M | 311M | 705M | 227M |
| Free Cash Flow | 200M | 218M | -33.2M | -114M | -49.4M | -562M | -40.4M |
| Ratios | |||||||
| ROE | 17.4% | 18.5% | 10.3% | 12.0% | 15.8% | 13.2% | 10.4% |
| ROA | 9.5% | 10.4% | 5.5% | 6.0% | 7.3% | 5.7% | 4.2% |
| Net Profit Margin | 17.9% | 18.7% | 12.5% | 13.8% | 17.2% | 16.9% | 13.3% |
| Debt to Equity | 0.59x | 0.59x | 0.70x | 0.78x | 0.88x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Synbio Tech Inc. dividends
- Dividend yield
- 6.51%
- Forward dividend
- 2.99 TWD
- Payout ratio
- 62.4%
- Ex-dividend date
- Mar 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 110M | 3.17 | 62.4% |
| 2024 | TWD 46.1M | 1.46 | 27.1% |
| 2023 | TWD 61.5M | 1.95 | 54.3% |
| 2022 | TWD 70.2M | 2.23 | 75.8% |
| 2021 | TWD 60.4M | 1.94 | 37.8% |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1020:1000 on Aug 6, 2024.
Who owns Synbio Tech Inc.
- Insiders 49.13%
- Institutions 0.00%
- Public & others 50.88%
- Shares outstanding 37.6M
- Free float 13.5M
Synbio Tech Inc. company profile
- Company name
- Synbio Tech Inc.
- Ticker
- 1295.TWO
- ISIN
- TW0001295004
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 66, Beiling 6th Road, Kaohsiung, Taiwan, 821
- Phone
- 886 7 6955 680
- Website
- synbiotech.com
About Synbio Tech Inc.
Synbio Tech Inc. manufactures and sells human healthcare products and probiotics for animals. It offers lactobacillus plantarum powder and derivatives of fermented lactic acid bacteria, as well as probiotics for dietary supplements, pets, economic animals, and plant preservation. The company also provides single probiotic strain and multi strain probiotics, and functional strain. Its functional strain includes SynForU-MemoryUp, a solution for brain health; Lactobacillus plantarum TWK10 for exercise performance; ABKEFIR to improve digestive and promote human health; SynForU-ImmuUp for immune system; SynForU-GastroKeep, a stomach care probiotic; SynForU-HepaAid, a liver care probiotic; SynForU-HerCare, which inhibits the growth of fungal and bacterial pathogens, as well as maintains the vaginal microbiome in proper balance; multi strain probiotics; and postbiotics, which include LDL557, for modulate the immune system, reduce inflammation and joint pain, and M1, to support immune system. In addition, it offers GABAbiotics-Adaptogenic Postbiotics, Synbio-Oligo, and Yogurt Powder for food applications; pet health solutions, including SYNPET functional probiotics, SYNPET GO for muscle and joint care, SYNPET IMMU for skin and immunity care, SYNPET FIT for weight management, and SYNPET TRENAL for kidney health care and functional prebiotics. Further, the company provides SYNFERM Pigment, a lactobacillus strains that rapidly produce lactic acid; SYNFERM Feed for digestion and rapid nutrient uptake in poultry and livestock; and SYNFERM Corn Silage for ruminant animals with high digestible nutrients. Additionally, it offers SYNSEA FeedAd, a probiotic complex for aquatic livestock; and SYNSEA Clean EX for reduction in the concentrations of nitrites and ammonia in water, as well as antibiotic-free probiotic solutions for poultry, swine, aquaculture, ruminant, and pigmented plants. The company was incorporated in 2000 and is based in Kaohsiung, Taiwan.
Synbio Tech Inc. management
6- San-Lian YangGM & Director
- Hsiu-Ju ChangAccounting Supervisor
- Chuan-Xian YangGM & Corporate Director Representative
- Kui-Ming LiDeputy General Manager
- Mr. Jin-Sheng LinDeputy General Manager
- Yi-Ru ZhangDeputy General Manager